MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Amgen Inc

Затворен

СекторЗдравеопазване

310.17 1.39

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

305.51

Максимум

313.95

Ключови измерители

By Trading Economics

Приходи

-2.2B

627M

Продажби

586M

9.1B

P/E

Средно за сектора

41.156

63.778

EPS

5.31

Дивидентна доходност

3.06

Марж на печалбата

6.901

Служители

28,000

EBITDA

-517M

2.9B

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+8.74% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.06%

2.39%

Следващи печалби

1.05.2025 г.

Следваща дата на дивидент

6.06.2025 г.

Следваща дата на екс-дивидент

16.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

14B

167B

Предишно отваряне

308.78

Предишно затваряне

310.17

Настроения в новините

By Acuity

50%

50%

180 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Amgen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.02.2025 г., 21:29 ч. UTC

Печалби

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30.10.2024 г., 20:18 ч. UTC

Печалби

Amgen Posts Higher 3Q Sales on Strong Demand

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4.02.2025 г., 21:02 ч. UTC

Печалби

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen 4Q Adj EPS $5.31 >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen 4Q Rev $9.1B >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen 4Q EPS $1.16 >AMGN

4.02.2025 г., 21:01 ч. UTC

Печалби

Amgen 4Q Net $627M >AMGN

28.01.2025 г., 10:30 ч. UTC

Топ новини

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27.12.2024 г., 07:00 ч. UTC

Печалби

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23.12.2024 г., 15:04 ч. UTC

Топ новини

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13.12.2024 г., 14:53 ч. UTC

Топ новини

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30.11.2024 г., 12:00 ч. UTC

Топ новини

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26.11.2024 г., 12:34 ч. UTC

Топ новини

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4.11.2024 г., 12:00 ч. UTC

Топ новини

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30.10.2024 г., 20:02 ч. UTC

Печалби

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30.10.2024 г., 20:02 ч. UTC

Печалби

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30.10.2024 г., 20:02 ч. UTC

Печалби

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30.10.2024 г., 20:02 ч. UTC

Печалби

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30.10.2024 г., 20:02 ч. UTC

Печалби

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30.10.2024 г., 20:01 ч. UTC

Печалби

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30.10.2024 г., 20:01 ч. UTC

Печалби

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30.10.2024 г., 20:01 ч. UTC

Печалби

Amgen 3Q Worldwide Neulasta Sales $110M >AMGN

Сравнение с други в отрасъла

Ценова промяна

Amgen Inc Прогноза

Ценова цел

By TipRanks

8.74% нагоре

12-месечна прогноза

Среден 332.43 USD  8.74%

Висок 389 USD

Нисък 280 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Amgen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

11

Купи

6

Задържане

1

Продай

Техническа оценка

By Trading Central

304.35 / 315.75Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Strong Bullish Evidence

Настроение

By Acuity

180 / 386 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.